Harmony Biosciences Third Quarter 2026 Financial Results - HARMONY BIOSCIENCES HOLDINGS INC

Financial Performance:

• Q3 2026 net revenue reached $269 million, a year-over-year increase from $239 million, driven by sustained demand for Wakix.
• Cost of sales increased to 30% of net revenue (vs. 25% YoY) primarily due to a new royalty associated with the Novidium license agreement.
• Total operating expenses were $134 million, up from $114 million YoY, driven by a $25 million milestone charge to MSN Labs, R&D investments, and commercial team expansion, partially offset by a $15 million clinical milestone credit in the prior year.
• Net income for the quarter was $48 million ($0.81 per diluted share), down from $51 million ($0.87 per share) in the prior year.
• The company ended Q3 2026 with over $1 billion in cash, cash equivalents, and investments, and $150 million in debt.
• Reiterated full-year 2026 net revenue guidance for Wakix of $1.0 to $1.04 billion, placing the company on track to exceed $1 billion in annual revenue for the first time.

Guidance and Future Outlook:

• Four-year guidance for Wakix net revenue remains $1.0 to $1.04 billion.
• BP205 Phase 2 studies across multiple CNS indications are planned to initiate in mid-2027.
• Pitolazine-GR (Pitocin-GR) is on track for launch in the first half of 2027, with a PDUFA date of April 1, 2027.
• Pitolazine-HD Phase 3 trials (OnStreet1 for narcolepsy, OnStreet2 for idiopathic hypersomnia) are ongoing, with top-line data expected in 2027 and PDUFA dates in 2028.
• Wakix Phase 3 TEMPO study in Prader-Willi syndrome is recruiting, with top-line data expected mid-2027 and PDUFA in 2028.
• Epilepsy franchise EPX100 Phase 3 trials (Lighthouse for Lennox-Gastaut, ORCIS for Dravet) expect top-line data mid-2027 and PDUFA in 2028.

Business Segments and Product Lines:

• Wakix (Pitolisane): Delivered $269 million in net product revenue with 9,350 average patients; achieved 400 net patient additions in the quarter, marking the fifth consecutive quarter (of the last six) of such growth.
• BP205: A potent Orexin-2 receptor agonist; preliminary Phase 1 Multiple Ascending Dose (MAD) data showed a favorable safety profile with mean Tmax of ~60 minutes and half-life of ~29 hours supporting once-daily dosing.
• Pitolazine-GR: Enteric-coated formulation allowing therapeutic dosing without titration; expected to launch H1 2027.
• Pitolazine-HD: Enhanced formulation with up to double the highest labeled dose of Wakix for fatigue and sleep inertia; life cycle management tool extending franchise value.
• Amorphous Pitolazine: Licensed from Novidium with patent protection until 2042; targeted for broader neuropsychiatric indications and new delivery modes.
• New Products: Wakix-GR launching in H1 2027; Orzapil (Takeda's competitor) expected to launch imminently with DEA scheduling expected to wrap up.

Market and Competitive Landscape:

• Wakix maintains a unique position as the only non-scheduled treatment for excessive daytime sleepiness and cataplexy in adults and pediatric patients with narcolepsy.
• Market penetration remains low with only ~20% of the estimated 170,000 U.S. narcolepsy patients diagnosed and treated.
• Over 80% of patients have payer coverage for Wakix.
• Competitive threat from Orzapil is acknowledged but deemed manageable as Orzapil is indicated only for Type 1 narcolepsy, whereas Wakix has broad utility for Type 1, Type 2, and pediatric patients.
• Company views BP205 as having a "best-in-class" profile compared to other Orexin-2 agonists in development due to higher potency and selectivity.

Risks and Challenges:

• Litigation: Active patent litigation against AET Pharma (Polymorph 197 and Method of Use 947 patents) and Novidium/Sandoz (Amorphous 920 patent); bench trial concluded, with rulings expected around the 30-month stay expiration in February 2027.
• Generic Launch Risk: While Harmony seeks a preliminary injunction against AET to block launch until the stay expires, there is a risk of an at-risk generic launch if the court rules unfavorably on the initial patents.
• Financial Risks: Increased cost of sales due to the Novidium royalty; potential milestone charges.
• Clinical Risks: On-target adverse events (insomnia, urinary frequency/urgency) for BP205; while mild, they may require dose optimization to balance efficacy and tolerability in patients.

Management Commentary and Tone:

• CEO Jeffrey Jano announced his resignation effective December 31, 2026, with Peter Anastasiou (COO) succeeding him as President and CEO effective January 1, 2027.
• Management tone is highly confident, describing the company as executing from a "position of strength" with a "robust pipeline" and "strong balance sheet."
• Leadership emphasizes continuity of strategic priorities (growing Wakix, advancing pipeline, business development, protecting IP) and views the transition as non-disruptive.
• Management expressed strong conviction in the "best-in-class" potential of BP205 and the long-term exclusivity of the Wakix franchise through 2030.

Analyst Questions and Answers:

• BP205 Dosing: Management confirmed confidence in once-daily dosing for BP205 based on half-life and target engagement data; split dosing is not currently planned.
• BP205 Safety: Headache rates were ~25% (mild, no discontinuations); insomnia and urinary frequency/urgency were <20% and not dose-limiting at the study doses.
• Competitive Launch: Wakix expected to maintain growth momentum through the launch of Orzapil, which is indicated only for NT1.
• Litigation Strategy: Harmony is requesting a preliminary injunction to prevent at-risk launches; management asserts confidence in prevailing on at least one of the three key patents (Polymorph, Method of Use, Amorphous).
• Cost of Sales: The 30% cost of sales reflects the new Novidium royalty and is expected to continue forward; no inventory fluctuation impacts in Q3.
• Amorphous Strategy: The amorphous form is distinct from Wakix and Pitolazine-HD, intended for broader indications like fatigue and neuropsychiatric disorders.

Other Key Points:

• Harmony has settled with six of seven ANDA filers, leaving only AET in active litigation.
• The company has secured exclusive rights to a new patent covering methods of making amorphous pitolisane hydrochloride from MSN Labs.
• A potential synergistic effect between BP205 (Orexin-2 agonist) and histaminergic agents (like Wakix/Pitolazine) was presented, suggesting a new therapeutic approach for narcolepsy.
• Wakix has added 400 net patients in five of the last six quarters, a significant acceleration compared to prior years.